title: A prospective study of the development of growth hormone deficiency in children given cranial irradiation, and its relation to statural growth.
abstract: Although GH deficiency (GHD) is the most frequent hormonal abnormality that occurs after cranial radiation, the natural course of this complication and its relationship to growth in children are not known. Therefore, we undertook a 2-yr prospective study of 16 children, aged 1.7-15 yr at the time of treatment, who received cranial [31-42 Gy (1 Gy = 100 rads)] and spinal radiation for medulloblastoma or ependymoma (group I). Their growth was compared to that of 11 children given similar doses of cranial radiation only (group II). The mean plasma GH response to arginine-insulin test (AITT) was 9.1 +/- 1.5 (+/- SE) micrograms/L in group I and 8.5 +/- 1.8 micrograms/L in group II (P = NS). After 2 yr, 16 of the 27 children had a peak plasma GH value below 8 micrograms/L after AITT, and 10 children had a peak response less than 5 micrograms/L. In addition, in group I, AITT and sleep-related GH secretion were compared; at the 2 yr follow-up only 3 of 13 children had discrepant results. At the 2 yr follow-up children treated by cranial and spinal radiation had a mean height of -1.46 +/- 0.40 SD below the normal mean. In contrast, the children given only cranial radiation had a mean height of -0.15 +/- 0.18 SD; P less than 0.02. Therefore, most of the growth retardation appeared to be due to lack of spinal growth. GHD is thus an early complication of cranial radiation in these children, and no significant growth retardation can be attributed to GHD during the first 2 yr. These data contribute to the organization of follow-up in irradiated children in order to decide when human GH treatment is necessary.
authors.affiliation: Pediatric Endocrinology Unit, Hôpital des Enfants-Malades, Paris, France.
authors.forename: R
authors.initials: R
authors.lastname: Brauner
authors.forename: R
authors.initials: R
authors.lastname: Rappaport
authors.forename: C
authors.initials: C
authors.lastname: Prevot
authors.forename: P
authors.initials: P
authors.lastname: Czernichow
authors.forename: J M
authors.initials: JM
authors.lastname: Zucker
authors.forename: P
authors.initials: P
authors.lastname: Bataini
authors.forename: J
authors.initials: J
authors.lastname: Lemerle
authors.forename: D
authors.initials: D
authors.lastname: Sarrazin
authors.forename: H J
authors.initials: HJ
authors.lastname: Guyda
mesh_terms: D000293:Adolescent; D000367:Age Factors; D001932:Brain Neoplasms / Q000532:radiotherapy*; D002528:Cerebellar Neoplasms / Q000532:radiotherapy; D004806:Ependymoma / Q000532:radiotherapy; D005260:Female; D006130:Growth Disorders / Q000209:etiology*; D013006:Growth Hormone / Q000097:blood / Q000172:deficiency*; D006801:Humans; D007031:Hypothalamus / Q000528:radiation effects*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives; D007334:Insulin-Like Growth Factor I / Q000097:blood; D008297:Male; D008527:Medulloblastoma / Q000532:radiotherapy; D010902:Pituitary Gland / Q000378:metabolism / Q000528:radiation effects*; D013125:Spinal Neoplasms / Q000532:radiotherapy; D013997:Time Factors
chemical_list: D007328:Insulin; C056863:insulin, Arg(B29)-; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone